Clinical Trial Update: CD40 Agonist and PD-1 Inhibitor in HNSCC [Phase 1]

View source ↗

Summary

A Phase 1 study at the University of Pennsylvania is evaluating the combination of a CD40 agonist and a PD-1 inhibitor for head and neck squamous cell carcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• CD40 agonist
• PD-1 inhibitor

Snippet

Sponsor: University of Pennsylvania | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING